Calvert Laboratories inks deal with Particle Sciences on early-stage development
Calvert Laboratories and Particle Sciences, two CROs in the fields of preclinical toxicology and drug product formulation, have joined forces to offer a streamlined solution to expedite preclinical drug development activities.
This partnership aims to alleviate delay issues by aligning formulation and preclinical experts, enabling them to identify the problem and realize the solution more quickly. Through this collaboration, Particle Sciences develops a formulation specifically aimed at achieving the desired exposure levels to allow Calvert Labs to seamlessly carry out the testing component of the project.
“Formulation is often one of the most significant challenges our clients’ face. The sooner we can resolve any issues, the more quickly we can help them advance their program forward,” said Charles B. Spainhour, V.M.D, Ph.D., president and chief scientific officer, Calvert Labs.
Mark Mitchnick, M.D., CEO of Particle Sciences, added, “No single group has the in-depth expertise in both formulation and toxicology needed to tackle this. Through this combined effort, under a single scope of work, our clients are getting a very valuable service unavailable anywhere else.”